Cmed Presents Smart Monitoring and eSource at the ACDM Annual Conference
Cmed, an innovative technology-led CRO, will present “Risk-Based Monitoring, Remote Monitoring and eSource: The Unattainable Trilogy of Monitoring?” at the ACDM Annual Conference being held in Brussels on Tuesday, March 14, 2017.
In this presentation, Stephanie Langouet, Cmed’s Vice President of Data and Analytics, will explore the practical implementation of more effective monitoring strategies, from traditional 100% Source Data Verification (SDV) to Risk-Based Monitoring (RBM) and increased remote review, and will assess the impact on site monitoring and clinical data management activities. She will touch upon several themes, including the role of data management at the heart of central reviews and the development of analytics tools, as well the benefits of direct capture of source data (eSource). She will also examine how a flexible combination of RBM, Remote Monitoring and eSource, supported by effective and operational processes, can reduce costs and enable smarter trials. This presentation will take place at 11.05am.
In addition, Langouet will participate in the panel discussion with other industry leaders. Attendees will also have the opportunity to meet with her and find out how Cmed’s encapsia™ clinical data suite, as well as Cmed’s portfolio of CRO service offerings, which includes both full service and clinical data management and biostatistics functional service provision, can help support the effective delivery of clinical trials.
encapsia™ is the first App based new generation clinical data suite, providing a much needed solution to the ever-rising complexity and cost of clinical research. With new and better options to collect, query, clean, visualize and analyze clinical data in real time, all within one clinical data suite, encapsia™ allows Cmed to significantly enhance the delivery of clinical trials.
To schedule a meeting with Langouet during the ACDM annual conference, email her at email@example.com .
- ends -
Cmed is an innovative, full service technology-led CRO. Cmed brings together experienced people and technology, providing customers with a friendly, proactive service, and delivers this service using advanced clinical data capture, management and reporting software and processes. Cmed’s new generation clinical data suite, encapsia™, streamlines the capture, management and reporting of clinical data, saving customers time and money. Clinical data can be captured flexibly by eSource, multi-media and web eDC, while being displayed in live visual insights, providing live analytics, and allowing within suite audit trailed actions. It is fully compliant with regulatory guidelines, and allows integration with existing systems. For more information visit www.cmedresearch.com .
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ASTRAZENECA10.12.2017 23:47 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials
NJ-CELGENE/BLUEBIRD-BIO10.12.2017 16:32 | pressemeddelelse
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
GA-GILEAD-SCIENCES/KITE10.12.2017 16:32 | pressemeddelelse
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
MA-TAKEDA/SEATTLE10.12.2017 14:02 | pressemeddelelse
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
ASTRAZENECA9.12.2017 19:02 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial
JANSSEN9.12.2017 18:21 | pressemeddelelse
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum